07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

Flammacerium cerium nitrate/silver sulfadiazine regulatory update

Sinclair said FDA granted Orphan Drug designation to Flammacerium cerium nitrate/silver sulfadiazine cream to treat patients with severe dermal burns. The company said the product is used in cases where surgical excision and grafting are...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Company News

Sinclair IS Pharma, Hikma Pharmaceuticals sales and marketing update

Under a 10-year deal, Sinclair granted Hikma exclusive rights to commercialize Flammacerium in 18 countries within the Middle East and North Africa region. The first launches are expected in late 2014 or early 2015. The...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

IS Pharma, Sinclair deal

The boards of both companies agreed to merge and form Sinclair IS Pharma plc . The newco, which will be headquartered in the U.K., will focus on developing therapies for dermatology, cancer, critical care and...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Company News

IS Pharma, Sinclair deal

IS Pharma and Sinclair said they are in advanced discussions for a potential merger of the biotechs. Under the potential deal terms, IS Pharma shareholders will receive 2.7 Sinclair shares per IS Pharma share. After...
00:54 , Aug 27, 2010 |  BC Extra  |  Financial News

Sinclair planning offering

Sinclair Pharma plc (LSE:SPH) plans to raise L19 million ($29.6 million) through the sale of 67.9 million shares at 28p in a placing and open offer underwritten by Singer Capital Markets. The price is an...
02:02 , Dec 11, 2009 |  BC Extra  |  Financial News

Sinclair raises L18.2 million

Sinclair Pharma plc (LSE:SPH) raised L18.2 million ($29.7 million) through the sale of 56.7 million shares at 32p in a placing and open offer. The price is a 29% discount to Sinclair's close of 45p...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Financial News

Sinclair amends placing and open offer

Sinclair Pharma plc (LSE:SPH), Godalming, U.K.   Business: Dermatology, Dental   Date announced: 10/29/09   Type: Placing and open offer   To be raised: Up to £18 million ($29.3 million)   Price: 32p   Investor:...
07:00 , Oct 19, 2009 |  BC Week In Review  |  Financial News

Sinclair proposes placing and open offer

Sinclair Pharma plc (LSE:SPH), Godalming, U.K.   Business: Dermatology, Dental   Date announced: 10/12/09   Type: Placing and open offer   To be raised: Up to £25 million ($39.4 million)   Shares: TBD   Price:...
07:00 , Oct 19, 2009 |  BC Week In Review  |  Company News

Sinclair, Solvay sales and marketing update

Sinclair will acquire worldwide rights, excluding the U.K. and Italy, to Flammazine and Flammacerium from Solvay for €17.5 million ($25.7 million). The silver sulfadiazine topical creams are marketed to treat and prevent infections in burn...
07:00 , Oct 19, 2009 |  BioCentury  |  Finance

Ebb & Flow

Armed with two Special Protocol Agreements from FDA, Amarin Corp. (NASDAQ:AMRN) has been able to resurrect its fortunes by convincing investors that a compound that disappointed in its original indication of Huntington's disease deserves a...